Literature DB >> 22608156

Cognitive and volumetric predictors of response to repetitive transcranial magnetic stimulation (rTMS) - a prospective follow-up study.

Christina P Furtado1, Kate E Hoy, Jerome J Maller, Greg Savage, Zafiris J Daskalakis, Paul B Fitzgerald.   

Abstract

As the prevalence of treatment resistant depression (TRD) continues to rise, it remains a clinically important issue to identify neurobiological-, patient- and treatment-related factors that could potentially predict response to treatment. Medial temporal lobe (MTL) structures, in particular the hippocampus and amygdala have been implicated in inferior treatment response. The role of related structures such as the entorhinal cortex and the impact of MTL abnormalities on neurocognitive function, however, have not been systematically examined. The current study investigated MTL abnormalities and neurocognitive characteristics of eventual treatment responders and non-responders to a course of repetitive transcranial magnetic stimulation (rTMS) in order to identify potential predictors of treatment outcome. Prior to rTMS treatment all patients underwent magnetic resonance imaging (MRI) and neuropsychological assessment. MRI analysis was conducted using FreeSurfer 5.0. There was a 50% response rate following up to a 6-week course of daily rTMS treatments. Treatment response was defined as 50% reduction in Hamilton Depression Rating Scale and BDI-II scores from baseline. There was no difference in pre-treatment neurocognitive profiles and MTL volumes between eventual treatment responders and non-responders. Smaller pre-treatment left hippocampus volume showed a trend towards predicting eventual subjective improvement in depressive symptomatology. Although preliminary, our findings suggest that structural abnormalities may have some potential for predicting outcome to rTMS.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22608156     DOI: 10.1016/j.pscychresns.2012.02.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Baseline Clinical and Neuroimaging Biomarkers of Treatment Response to High-Frequency rTMS Over the Left DLPFC for Resistant Depression.

Authors:  Ghina Harika-Germaneau; Issa Wassouf; Tom Le Tutour; Remy Guillevin; Damien Doolub; Reza Rostami; Alexia Delbreil; Nicolas Langbour; Nematollah Jaafari
Journal:  Front Psychiatry       Date:  2022-05-20       Impact factor: 5.435

Review 2.  Neuroimaging Mechanisms of Therapeutic Transcranial Magnetic Stimulation for Major Depressive Disorder.

Authors:  Noah S Philip; Jennifer Barredo; Emily Aiken; Linda L Carpenter
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-11-11

Review 3.  Biological markers in noninvasive brain stimulation trials in major depressive disorder: a systematic review.

Authors:  Thiago M Fidalgo; J Leon Morales-Quezada; Guilherme S C Muzy; Noelle M Chiavetta; Mariana E Mendonca; Marcus V B Santana; Oscar F Goncalves; Andre R Brunoni; Felipe Fregni
Journal:  J ECT       Date:  2014-03       Impact factor: 3.635

4.  More female patients and fewer stimuli per session are associated with the short-term antidepressant properties of repetitive transcranial magnetic stimulation (rTMS): a meta-analysis of 54 sham-controlled studies published between 1997-2013.

Authors:  Karina Karolina Kedzior; Valeriya Azorina; Sarah Kim Reitz
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-07       Impact factor: 2.570

5.  Neural and Behavioral Predictors of Treatment Efficacy on Mood Symptoms and Cognition in Mood Disorders: A Systematic Review.

Authors:  Ida Seeberg; Hanne L Kjaerstad; Kamilla W Miskowiak
Journal:  Front Psychiatry       Date:  2018-07-26       Impact factor: 4.157

6.  Cold Cognition as Predictor of Treatment Response to rTMS; A Retrospective Study on Patients With Unipolar and Bipolar Depression.

Authors:  Reza Rostami; Reza Kazemi; Zahra Nasiri; Somayeh Ataei; Abed L Hadipour; Nematollah Jaafari
Journal:  Front Hum Neurosci       Date:  2022-07-25       Impact factor: 3.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.